What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM”In the company’s words, NCT05808634 on ClinicalTrials.gov
- Tested for
- Advanced Adenocarcinoma
- Main trialPhase 1
- “The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma”In the company’s words, NCT05808634 on ClinicalTrials.gov
Other drugs for Advanced Adenocarcinoma
- PembrolizumabMerck & Co. · Phase 3
- EIK1001Eikon Therapeutics · Phase 2/3
- QL2107Qilu Pharmaceutical · Phase 3
- IFx-Hu2.0TuHURA Biosciences, Inc. · Phase 2/3
- FutibatinibTaiho · Phase 2/3
- MB11mAbxience Research S.L. · Phase 3
Coming up1
- 15 Sep 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 15 Sep 2028 | Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026